Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Salford
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Salford, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2863 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 11 Oct 2026, 03:15 UTC
2863
Studies in scope
industry-sponsored, all four open statuses
1385
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2015 Manchester 668 Birmingham 478 Glasgow 437 Cambridge 425
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Janssen Research & Development, LLC6 Novartis Pharmaceuticals6 argenx5 Sanofi5 Hoffmann-La Roche4
Site city
London2015 Manchester668 Birmingham478 Glasgow437 Cambridge425
All 429 cities
Target enrolment
to

Trials with a site in Salford

103 of 2863 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study
NCT07746895C3 Glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
DrugPegcetacoplan
Swedish Orphan Biovitrum
Phase 4
150
Cambridge, Cardiff, Glasgow, Leicester, London, Manchester, Newcastle, Salford
2026-08-05
Recruiting
VectivBio AG
Phase 3
124
London, Aberdeen, Birmingham, Salford
2026-08
Recruiting
Boehringer Ingelheim
Phase 3
448
Bristol, Leeds, London, Salford
2026-07-27
Recruiting
Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
NCT07486934Myotonic Dystrophy Type 1 (DM1), DM1, Myotonic Dystrophy, Steinert Disease
DrugZeleciment basivarsen
Dyne Therapeutics
Phase 3
150
London, Salford
2026-05-14
Recruiting
Vertex Pharmaceuticals Incorporated
Phase 2
30
Birmingham, London, Salford
2026-05-13
Recruiting
Eli Lilly and Company
Phase 2
60
London, Salford
2026-04-14
Recruiting
A Gaucher Disease Gene Therapy Trial With FLT201
NCT07223944Gaucher Disease Type 1
Spur Therapeutics
Phase 3
45
Birmingham, Salford, London, Cambridge
2026-04-07
Recruiting
JCR Pharmaceuticals Co., Ltd.
Observational
57
Belfast, Birmingham, London, Manchester, Salford
2026-03-25
Recruiting
Boehringer Ingelheim
Phase 2
132
Bradford, London, Salford
2026-03-23
Recruiting
Priovant Therapeutics, Inc.
Phase 2/3
342
Salford, Glasgow, Brighton, London, Wrexham
2026-03-19
Recruiting
Hoffmann-La Roche
Phase 2
360
Truro, London, Glasgow, Cardiff, Salford, Swansea
2026-03-10
Recruiting
Boehringer Ingelheim
Phase 3
286
Bebington, Bradford, Cambridge, Carshalton, Leicester, London, Middlesbrough, Salford
2026-02-16
Recruiting
Insmed Incorporated
Phase 3
344
London, Sheffield, Bath, Belfast, Glasgow, Salford, Southampton
2026-01-07
Active, closed
UCB Biopharma SRL
Phase 2
165
London, Salford
2025-12-29
Recruiting
UCB Biopharma SRL
Phase 3
320
London, Salford
2025-11-14
Recruiting
Shionogi
Phase 2
45
Birmingham, London, Newcastle upon Tyne, Salford
2025-10-30
Recruiting
Bristol-Myers Squibb
Phase 3
3,040
London, Southampton, Salford, Bristol, High Wycombe, Kirkcaldy
2025-09-22
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 2
30
Cambridge, Leicester, London, Salford
2025-09-19
Recruiting
Sanofi
Phase 3
942
Milton Keynes, London, Southampton, Salford, Chertsey, Reading, Rotherham
2025-09-17
Recruiting
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
NCT07091630Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
DrugEmpasiprubart
argenx
Phase 3
160
Nottingham, London, Salford
2025-09-16
Recruiting
LEO Pharma
Phase 2
135
Bristol, London, Newcastle upon Tyne, Salford, Stourbridge
2025-09-11
Recruiting
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
NCT06920004Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
DrugsEmpasiprubart·IVIG
argenx
Phase 3
218
Salford, Leeds, London
2025-08-22
Recruiting
Novartis Pharmaceuticals
Phase 2
407
Edinburgh, Oxford, Aberdeen, London, Newcastle upon Tyne, Salford, Southampton
2025-08-07
By invitation
MoonLake Immunotherapeutics AG
Phase 3
835
Leeds, Salford
2025-06-27
Recruiting
Immunovant Sciences GmbH
Phase 2
210
Cornwell, London, Merthyr Tydfil, Salford, Surrey
2025-06-19
Recruiting
Neurocrine Biosciences
Phase 3
200
London, Salford, Sheffield, Southampton
2025-05-30
Recruiting
Apogee Therapeutics, Inc.
Phase 2
350
Salford, London
2025-05-14
Active, closed
Janssen Research & Development, LLC
Phase 3
752
Dudley, Harrow, Kings Lynn, London, Reading, Salford, Southampton, Wakefield
2025-04-15
Recruiting
Immunovant Sciences GmbH
Phase 2
162
Bristol, Glasgow, Salford, Southampton
2025-03-18
Recruiting
Incyte Corporation
Phase 3
600
Birmingham, Dudley, Ipswich, Liverpool, London, Poole, Redhill, Salford
2025-02-28
Recruiting
Sanofi
Phase 2
84
Leicester, Salford, Oxford
2024-12-19
Active, closed
argenx
Phase 3
154
Glasgow, Oxford, Salford, Sheffield, Taunton
2024-12-18
Recruiting
PepGen Inc
Phase 2
24
Salford, London, Cardiff, Newcastle upon Tyne
2024-12-10
Active, closed
H. Lundbeck A/S
Phase 3
401
Salford, Oxford, Glasgow, Newcastle upon Tyne, Exeter, London
2024-12-03
Active, closed
Novartis Pharmaceuticals
Phase 4
24
Cambridge, London, Oxford, Salford
2024-11-25
Recruiting
Chiesi Farmaceutici S.p.A.
Observational
100
Edgbaston, Salford, London
2024-11-06
Active, closed
ModernaTX, Inc.
Phase 3
37,864
High Wycombe, Runcorn, Truro, London, Orpington, Blackpool, Rochdale, Salford
2024-09-24
Active, closed
Dianthus Therapeutics
Phase 2
46
London, Oxford, Salford
2024-09-17
Active, closed
Takeda
Phase 3
2,099
High Wycombe, Ilford, Salford, London, Harrow
2024-09-04
By invitation
Biohaven Therapeutics Ltd.
Phase 2
660
Swansea, Glasgow, Salford, Liverpool, Oxford, Cardiff, London, Newcastle upon Tyne
2024-07-30
Recruiting
Study of WAL0921 in Patients With Glomerular Kidney Diseases
NCT06466135Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy
Walden Biosciences
Phase 2
96
Derby, Leicester, London, Manchester, Salford
2024-07-02
Active, closed
Spur Therapeutics
Phase 1/2
75
Salford
2024-05-13
Active, closed
Biohaven Therapeutics Ltd.
Phase 2/3
390
Swansea, Glasgow, Salford, Oxford, Cardiff, London, Newcastle upon Tyne
2024-05-13
By invitation
Travere Therapeutics, Inc.
Phase 3
100
Birmingham, London, Salford
2024-04-30
Active, closed
A Study Evaluating APG777 in Atopic Dermatitis
NCT06395948Atopic Dermatitis
DrugAPG777
Apogee Therapeutics, Inc.
Phase 2
470
Salford, Dudley, London
2024-04-29
Active, closed
Janssen Research & Development, LLC
Phase 3
272
London, Salford, Southampton, Stevenage
2024-04-09
Active, closed
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
120
Manchester, London, Salford
2024-03-28
Active, closed
Eli Lilly and Company
Phase 3
320
Bristol, Edinburgh, Glasgow, Nuneaton, Preston, Rochdale, Salford, Stevenage
2024-03-15
Active, closed
Vertex Pharmaceuticals Incorporated
Phase 1/2
47
Glasgow, London, Salford, Sheffield
2024-02-20
Recruiting
Amicus Therapeutics
Observational
500
Birmingham, Cambridge, Cardiff, London, Manchester, Salford
2024-02-16
Active, closed
Astellas Gene Therapies
Not applicable
119
Cambridge, Newcastle upon Tyne, Salford
2024-02-01
Active, closed
Incyte Corporation
Phase 3
617
Birmingham, Dudley, Salford
2024-01-30
Active, closed
Janssen Research & Development, LLC
Phase 3
774
London, Reading, Salford, Southampton
2024-01-17
Recruiting
Travere Therapeutics, Inc.
Phase 3
70
Birmingham, London, Salford
2023-12-28
Active, closed
Sanofi
Phase 3
943
Gwent, Cardiff, Exeter, London, Newcastle upon Tyne, Inverness, Canterbury, Salford
2023-12-27
Recruiting
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
NCT06154252Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome, Immune-Mediated Necrotizing Myopathy
Cabaletta Bio
Phase 2/3
74
London, Manchester, Salford
2023-12-20
Recruiting
Biogen
Observational
20
London, Salford, Southampton, Nottingham, Oswestry, Sheffield, Newcastle upon Tyne, Birmingham
2023-12-15
Active, closed
Sanofi
Phase 3
1,655
Exeter, London, Inverness, Canterbury, Salford
2023-12-13
Active, closed
argenx
Observational
413
Bristol, Fulwood, Glasgow, Nottingham, Oxford, Salford, Sheffield, Taunton
2023-11-29
By invitation
Edgewise Therapeutics, Inc.
Phase 2
260
Salford, London, Newcastle
2023-11-02
Recruiting
Biogen
Observational
908
Salford
2023-10-27
Active, closed
Janssen Research & Development, LLC
Phase 3
684
Harrow, London, Reading, Salford
2023-10-12
Active, closed
Janssen Research & Development, LLC
Phase 3
311
Harrow, Salford, Southampton
2023-10-12
Recruiting
AbbVie
Phase 3
1,500
High Wycombe, Brighton, Gloucester, London, Oxford, Harrow, Salford
2023-10-11
Recruiting
Novartis Pharmaceuticals
Phase 3
106
Belfast, Cardiff, London, Manchester, Salford
2023-10-02
By invitation
argenx
Phase 3
240
Liverpool, London, Salford
2023-09-12
By invitation
Disc Medicine, Inc
Phase 2/3
230
London, Dundee, Salford
2023-08-31
Active, closed
Hoffmann-La Roche
Phase 3
459
Cambridge, Leicester, London, Oxford, Salford
2023-08-08
Active, closed
AC Immune SA
Phase 2
150
London, Salford
2023-07-24
Active, closed
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy
DrugZigakibart
Novartis Pharmaceuticals
Phase 3
383
Bristol, Brighton, Salford, Leicester, London, Nottingham
2023-07-06
Active, closed
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
NCT05696717Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
Theravance Biopharma
Phase 3
102
Birmingham, London, Salford
2023-06-27
Active, closed
AbbVie
Phase 3
1,328
London, Southampton, Coventry, Leeds, Bristol, Salford
2023-06-21
Recruiting
Pfizer
Phase 3
318
Glasgow, Salford, Doncaster
2023-05-20
By invitation
An Open-label Study of XEN1101 in Epilepsy
NCT05718817Focal Epilepsy, Tonic-Clonic Seizures
DrugAzetukalner
Xenon Pharmaceuticals Inc.
Phase 3
880
Leeds, Cardiff, Birmingham, London, Oxford, Salford
2023-04-25
Recruiting
Xenon Pharmaceuticals Inc.
Phase 3
160
Cardiff, Wakefield, London, Oxford, Salford
2023-02-14
Active, closed
Amicus Therapeutics
Phase 3
14
Salford
2022-10-31
Active, closed
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
NCT05347095Fistulizing Crohns Disease, Perianal Crohns Disease
DrugGuselkumab
Janssen-Cilag Ltd.
Phase 3
288
Hull, London, Newcastle upon Tyne, Salford
2022-09-27
Active, closed
Dyne Therapeutics
Phase 1/2
127
London, Newcastle upon Tyne, Salford
2022-09-05
Recruiting
Smith & Nephew, Inc.
Not applicable
234
Chertsey, Bath, Bristol, Salford
2022-08-30
Active, closed
Denali Therapeutics Inc.
Phase 2/3
65
London, Birmingham, Salford
2022-07-21
Recruiting
Ionis Pharmaceuticals, Inc.
Phase 1
40
London, Oxford, Salford, Southampton
2022-07-21
Active, closed
Janssen Research & Development, LLC
Phase 2
36
Edinburgh, London, Salford
2022-07-05
Active, closed
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
530
Cambridge, Gloucester, Leicester, London, Salford, Swansea
2022-03-15
Active, closed
Sanofi
Phase 3
122
Cambridge, London, Salford
2022-03-11
Recruiting
Hanmi Pharmaceutical Company Limited
Phase 2
18
Salford, London
2022-03-03
By invitation
UCB Biopharma SRL
Phase 3
300
Birmingham, Glasgow, London, Oxford, Salford
2022-02-03
Recruiting
UCB Biopharma SRL
Phase 3
350
Birmingham, Cardiff, Glasgow, London, Oxford, Salford
2021-12-07
Recruiting
Novartis Pharmaceuticals
Phase 3
540
Newcastle upon Tyne, Cambridge, Leicester, London, Salford
2021-09-20
Active, closed
VectivBio AG
Phase 3
158
Harrow, London, Salford
2021-07-13
Active, closed
Hoffmann-La Roche
Phase 3
751
Salford
2021-03-24
Active, closed
Neurocrine Biosciences
Phase 3
182
Cardiff, London, Manchester, Salford
2020-12-16
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
DrugsAtrasentan·Zigakibart
Novartis Pharmaceuticals
Phase 3
404
Bristol, Hertford, Leicester, London, Salford
2020-12-11
Active, closed
A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)
NCT04093349Pompe Disease, Pompe Disease (Late-onset), Glycogen Storage Disease Type 2, Glycogen Storage Disease Type II
Spark Therapeutics, Inc.
Phase 1/2
4
Birmingham, London, Salford
2020-10-01
Active, closed
Cold Agglutinin Disease Real World Evidence Registry
NCT05791708Cold Agglutinin Disease (CAD), Cold Agglutinin Syndrome (CAS)
RECORDATI GROUP
Observational
429
Truro, Carlisle, Gillingham, London, Salford, Airdrie, Newcastle upon Tyne, Middlesbrough
2019-12-12
Active, closed
Hoffmann-La Roche
Phase 3
1,013
Cardiff, Glasgow, Inverness, London, London, GT LON, Nottingham, Plymouth, Salford
2019-08-12
Active, closed
Ceramisys Ltd
Observational
220
Doncaster, Birmingham, North Shields, Salford, Stoke-on-Trent, Taunton
2019-06-13
Active, closed
Travere Therapeutics, Inc.
Phase 3
406
Reading, Cambridge, Middlesbrough, Derby, Brighton, London, Manchester, Salford
2018-12-11
Active, closed
Janssen-Cilag International NV
Observational
135
Cardiff, London, Salford
2017-10-25
Active, closed
Genzyme, a Sanofi Company
Phase 2
12
Cambridge, Salford
2017-01-04
Recruiting
Lysosomal Acid Lipase (LAL) Deficiency Registry
NCT01633489Lysosomal Acid Lipase Deficiency, Cholesterol Ester Storage Disease, Wolman Disease, Acid Cholesteryl Ester Hydrolase Deficiency, Type 2
Alexion Pharmaceuticals, Inc.
Observational
300
Cambridge, London, Manchester, Salford, Birmingham
2013-05-30
Recruiting
Pompe Disease Registry Protocol
NCT00231400Glycogen Storage Disease Type II, Pompe Disease
Genzyme, a Sanofi Company
Observational
2,000
Cambridge, Cardiff, Birmingham, London, Glasgow, Salford, Manchester, Newcastle upon Tyne
2004-09-15
Recruiting
Genzyme, a Sanofi Company
Observational
9,000
Cambridge, Birmingham, London, Salford, Belfast, Manchester
2001-07-31
Recruiting
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
NCT00358943Gaucher Disease, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease
Genzyme, a Sanofi Company
Observational
12,000
Cambridge, Birmingham, London, Salford, Manchester
1991-04-01
Rows per page Showing 1–103 of 103
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-uk/city/salford

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,863 studies in total at the last sync on 11 Oct 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 103 of those studies with a site in Salford.

How many clinical trials are recruiting in Salford?

49 of the 103 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:15 UTC sync. A further 0 have not yet opened recruitment, 46 are active but closed to new participants, and 8 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Salford), 103 studies
PhaseStudiesRecruitingShare
Phase 3522050.5%
Phase 2231522.3%
Observational13912.6%
Phase 2/3524.9%
Phase 1/2403.9%
Not applicable211.9%
Phase 1211.9%
Phase 4211.9%

Most active sponsors

Lead sponsors with the most studies (Salford)
Lead sponsorStudiesRecruiting
Janssen Research & Development, LLC60
Novartis Pharmaceuticals63
argenx52
Sanofi52
Genzyme, a Sanofi Company43
Hoffmann-La Roche41
UCB Biopharma SRL42
Boehringer Ingelheim33
Travere Therapeutics, Inc.31
AbbVie21
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.